Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients chronically infected with hepatitis C virus (HCV) genotype 1 or 4
HCV RNA viral load of ≥100,000 IU/mL
No previous exposure to interferon, pegIFNα, or RBV
Results of a liver biopsy demonstrating absence of cirrhosis obtained ≤24 months prior to randomization. Compensated cirrhotics with Hepatitis C virus genotype 1 infection are eligible, but will be capped at 10% of the randomized study population (biopsy can be from any time period prior to randomization)
Findings on ultrasound, computed tomography scan, or magnetic resonance imaging 12 months prior to randomization that do not demonstrate evidence of hepatocellular carcinoma
Body mass index of 18 to 35 kg/m\^2
You may not be if
Positive for hepatitis B or HIV-1/HIV-2 antibody at screening
Evidence of a medical condition associated with chronic liver disease other than HCV
Evidence of decompensated cirrhosis based on radiologic criteria or biopsy
Clareo Health | Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
